IMPACT Therapeutics (HKG:7630) will be added to the Hang Seng Composite Index from Sept. 7, according to a Monday Hong Kong bourse filing.
Its shares are also expected to meet the criteria to be traded through the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.
Zhongji Innolight (HKG:3308, SHE:300308) reported 13.7 billion yuan in profit attributable to owners for the first half, compared with 4 billion yuan a year ago, a Friday bourse filing showed.EPS moved to 12.19 yuan from 3.60 yuan year over year.For the six months ended June 30, revenue was 41.8 billion yuan, versus 14.8 billion yuan previously, the optical interconnect service provider said.The company declared an interim dividend of 12 yuan per 10 shares. Dividends to holders of Hong Kong-listed shares of record as of Sept. 10 will be payable on Oct. 9.
Shanghai Henlius Biotech (HKG:2696) reported 430.4 million yuan in profit attributable to equity holders of the parent for the first half, compared with 390.1 million yuan a year ago, a Friday bourse filing showed.EPS moved to 0.79 yuan from 0.72 yuan year over year.For the six months ended June 30, revenue was 3.59 billion yuan, versus 2.82 billion yuan, the biologics medicine company said.
Toll revenue of a majority of Yuexiu Transport Infrastructure's (HKG:1052) expressways declined year on year for the month of July, mainly due to a decrease in toll traffic volume for most of the company-operated expressways during the reporting monthAmong the company's expressways, the GNSR Expressway posted the highest toll revenue of 83.3 million yuan with an average daily toll traffic volume of 309,225, a Friday Hong Kong bourse filing said. The expressway recorded a 6.5% year-on-year decline in toll traffic volume.Han'e Expressway recorded the biggest year-on-year decline in toll revenue, decreasing by 63% to 11.1 million yuan.